Abstract Library

#4147 5-Hydroxymethylcytosine profiling of plasma-derived circulating free DNA in patients with pancreatic neuroendocrine tumors treated with [177Lu]Lu-DOTA-TATE

Introduction: Cell-free DNA (cfDNA) 5-hydroxymethylcystosine (5hmC) analysis, a novel epigenomic technology, can detect changes in tumor gene expression and regulation in liquid biopsies.

Conference:

Presenting Author:

Authors: Sponheim J, Wong C, Thiis-Evensen E, Coruh C, Ning Y,

Keywords: [177Lu]Lu-DOTA-TATE, Lutathera, Peptide Receptor Radionuclide Therapy, Radioligand Therapy, Pancreatic Neuroendocrine Tumor, Biobank, 5-Hydroxymethylation,

#3963 Infrastructure FOr Rare Cancer in the NEtherlands, towards a comprehensive platform for early detection and diagnosis of rare cancers (FORCE), and especially neuroendocrine neoplasms (NEN)

Introduction: NEN consist of a heterogeneous group of rare tumors. For these patients, clinical trials requiring a high number of patients are often infeasible. Often, the prognosis is poor due to late diagnosis and fewer available treatment options as compared to patients with common cancer types. In common cancers, ultrasensitive molecular profiling of circulating cell-free DNA (USccfDNA) based tests are promising to improve diagnosis, detection of minimal residual disease (MRD), and recurrence. Data needed to apply USccfDNA in NEN is lacking.

Conference:

Presenting Author:

Authors: de Hosson L, Pieterman C, Fehrmann R, de Herder W, Jalving M,

Keywords: circulating cell free DNA, biobank, databank, early detection,

#3133 Establishment of neuroendocrine neoplasms organoid biobank enables genotype-phenotype mapping

Introduction: Gastroentero-pancreatic (GEP) neuroendocrine neoplasm (NEN) that consists of neuroendocrine tumor (NET) and neuroendocrine carcinoma (NEC) is a lethal but under-investigated disease owing to its rarity. Incidence of this disease is recently increasing, and novel treatment is warranted. However, the establishment and application of GEP-NEN disease models have been limited.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Kawasaki K, Fujii M, Kudo A, Kanai T, Nakagawa H,

Keywords: organoids, CRISPR-Cas9, multi-omics analysis, gastrinoma, MiNEN,

#3056 Multi-Omic Characterization and Evolution of Neuroendocrine Neoplasm Organoids

Introduction: Molecular characterizations of neuroendocrine neoplasm (NENs) have unveiled candidate alterations associated with aggressiveness and suggested that the molecular link between neuroendocrine tumors (NETs) and neuroendocrine carcinomas (NECs) might be subtler than initially thought. For example, we have recently unveiled a new entity of pulmonary carcinoids (supra-carcinoids) with carcinoid-like morphology yet the molecular and clinical features of large cell neuroendocrine carcinoma (LCNEC). Testing hypotheses to explain aggressiveness and the possibility of progression or transition from NET to NEC through the accumulation of genetic anomalies requires in vitro and in vivo experimental models.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Foll M

Authors: Alcala N, Dayton T, Mangiante L, Delhomme T, Tabone-Egling S,

Keywords: organoids, omics, evolution, lung, pancreas, bioinformatics,

#3049 Organoid Models of Neuroendocrine Cell Growth and Tumorigenesis

Introduction: A paucity of in vitro and in vivo models has limited the study of Neuroendocrine neoplasms (NENs). Moreover, little is known about normal neuroendocrine (NE) cells and how they contribute to NEN formation.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Dayton T, Den Hartigh L, Levy S, van den Berg J, Kok N,

Keywords: Organoids, NENs, pulmonary neuroendocrine cells,